Table 2.
The clinical results of HID and HID comparing with MRD or URD or CBT
| Author | HSCT type | Case number | Diagnosis | TRM | CIR | aGVHD | OS | LFS |
|---|---|---|---|---|---|---|---|---|
| Wang et al. [18], 2015 | HID vs MSD multicenter, prospective | 231 vs219 | Adults IR/HR AML-CR1 | 3 years, 13 vs 8% | 3 years, 15 vs 15% | 3 years, 79 vs 82% | 3 years, 74 vs 78% | |
| Liu et al. [61], 2013 | HID vs MSD | 212 vs 46 | Pediatric AL | II–IV* 40.8 vs 20%; III–IV 14.3 vs 16.9% | 77.8 vs 65.5% | 68.9 vs 52.5% (ALL-CR1); 82.5% vs 71.7% (AML-CR1) | ||
| Wang et al. [17], 2016 | HID ns MSD Adults Phase II randomizes | 121 vs 89 | (Ph-)ALL-CR1(HR) | 3 years, 18 vs 24% | 3 years, 61 vs 60% | |||
| Chen et al. [43], 2015 | HID vs MSD | 101 vs 38 | Ph + ALL | 15.6% at 5 years | 20.3% at 5 years | 74.0 vs 68% at 5 years | 65.8 vs 61% at 5 years | |
| Gao et al. [44], 2015 | HID vs MSD | 47 vs 35 | Ph + ALL | 21.3 vs 17.1% | 19.1* vs 44.8%. | III–IV 17.0 vs 11.4% | 2 years, 63.8 vs 62.6% | 2 years, 59.5 vs 45.7% |
| Wang et al. [19], 2016 CBMTR data based | HIDs vs MRD | 136 (3/6) vs 90(4/6) vs 228 | MDS | 58 vs 63 vs 73% | 58%*, 63 vs 71% | |||
| Ma et al. [64], 2016 | HID vs MSD | 67 vs 23 | CML-BC | 3 years, 60.0 vs 55.3% | 3 years, 51.1 vs 47.8% | |||
| Xu et al. [33], 2016 | HID vs MSD\prospective | 101 vs 48 | SAA failure to previous IST | II–IV* 33.7 vs 4.2%; III–IV, 7.9 vs 2.1% | 3 years, 89.0 vs. 91.0% | 3-year FFS 86.8 vs. 80.3% | ||
| Xu et al. [34], 2017 | HID vs MSD Data based | 89 vs 69 | SAA, upfront | 97.8 vs 97.1% | II–IV* 30.3 vs. 1.5%, III–IV* 10.1 vs. 1.5% | 3 years, 86.1 vs 91.3% | 3-year FFS 85.0 vs 89.8% | |
| Sun [79], 2016 | HID vs URD, Pair-match | 87 vs 87 | AML-CR1 | 13.8 vs 15.7% | 12.7 vs 24% | III–IV 9.2 vs 9.4% | 5 years, 78.2 vs 63.6% | 5 years, 73.5 vs 60.3% |
| Huang et al. [13], 2009 | HID vs URD | 219 vs 78 | Malignant | 2 years, 20 vs 18% | 2 years, 12 vs 18% | II–IV 47 vs 31% | 4 years, 74 vs 74% | 4 years, 67 vs 61% |
| Han et al. [39], 2017 | HID, vs MSD vs MUD | 127 vs 144 vs 77 | Adult patients | 16.4 vs 11.6 vs 19.6% | 14.8 vs 21.1 vs 16.7% | III–IV 11.4 vs 7.7 vs 13.5% | 70.1 vs, 73.7 vs 69.8% | 5-years DFS 68.7 vs 67.3 vs 63.7% |
| Luo et al. [23], 2014 | HRD vs URD vs MSD prospective ChiCTR-OCH-12002490 | 99 vs 116 vs 90 | Hematologic malignancies | 30.5 vs 22 vs 4.7%* | 14.2* vs 21.2 vs 34%; 15.4* vs 28.2 vs 49.9% (in HR pts) | II–IV 42.4 vs 39.7 vs 15.6% | 60.8 vs 63.5 vs 77.2%, | 58.3 vs 58.4, vs 63.6% |
| Mo et al. [81], 2016 | HID vs CBT multiple centers | 65 vs 64 | ALL (HR) pediatric | 2 years, 12.8 vs 18.8% | 2 years, 16.1 vs 24.1% | 2 years, 82 vs 69.6% | 2 years, 71 vs 57.2%* |
OS overall survival, RR relapse rate, LFS leukemia-free survival, HID haploidentical donor, MRD matched related donor, HSCT hematopoietic stem cell transplantation, MRD matched related donor, CBT cord blood transplantation, URD unrelated donor, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, MDS myelodysplastic syndrome, LR low risk, IR intermediate risk, HR high risk, T_ALL T cell ALL, MR molecular response, ph Philadephia chromosome[t(9;22)], CML chronic myeloid leukemia, CP chronic phase, AP accelerated phase, BC blast crisis, IM imatinib, TKI2 second-generation TKI, SAA severe aplastic anemia. * The difference was significance between two groups (P<0.05)